| Mean ± SD | No. pts. | (%) | ||
| Age (yrs.) | 68.3 ± 6.7 | |||
| Prostate volume (mL) | 23.5 ± 7.8 | |||
| Initial PSA (ng/mL) | 9.7 ± 9.7 | |||
| <10 | 154 | 69 | ||
| 10 - <20 | 60 | 27 | ||
| ≥20 | 10 | 4 | ||
| Gleason score | ≤6 | 69 | 31 | |
| 7 | 105 | 47 | ||
| ≥8 | 50 | 22 | ||
| Clinical diagnosis | T1b | 13 | 6 | |
| T1c | 105 | 47 | ||
| T2a | 76 | 34 | ||
| T2b | 23 | 10 | ||
| T2c | 7 | 3 | ||
| Risk group | Low | 54 | 24 | |
| Intermediate | 111 | 50 | ||
| High | 59 | 26 | ||
| Treatment before HIFU | ADT ≥ 3 months | 59 | 26 | |
| TUR-P | 28 | 13 | ||